PTC Therapeutics (PTCT) PT Raised to $43 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
PTC Therapeutics (PTCT) PT Raised to $51 at RBC Capital
August 8, 2018 8:50 AM EDTRBC Capital raised its price target on PTC Therapeutics (NASDAQ: PTCT) to $51.00 (from $48.00) while maintaining a Outperform rating.
Abrahams expects the stock to gain as it continues to leverage their DMD cash flows and commercial/R&D infrastructure to diversify into new... More
